Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
about
Regeneration of stalled immune responses to transformed and infected cells using γδ T cellsWhat lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A ReviewImmune regulation of bone metastasisAdoptive cell therapy for sarcomaγδ T cells for cancer immunotherapy: A systematic review of clinical trialsHarnessing the power of Vδ2 cells in cancer immunotherapyStructures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthasesLipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR InvestigationTernary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme’s active site closureγδ T cells in cancer immunotherapyPhosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primatesInterferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infectionA Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid ComponentsA rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infectionsHighly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.Human cytomegalovirus elicits fetal gammadelta T cell responses in uteroInhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Immunotherapy for the treatment of prostate cancer.Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells.Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.Full restoration of Brucella-infected dendritic cell functionality through Vγ9Vδ2 T helper type 1 crosstalk.Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Targeting γδ T cells for immunotherapy of HIV diseasePreferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Plasticity of γδ T Cells: Impact on the Anti-Tumor ResponseClinical applications of gamma delta T cells with multivalent immunity.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRsRapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire
P2860
Q26823185-1B194B56-BC3A-4CB6-B722-8F966DDBD295Q26849323-A949EB61-A812-4BBC-9393-66E36D555AD8Q26995102-73CDC7C3-3448-4459-B1AB-3630EF8DABE6Q27005871-158EB3B4-DE60-417B-9681-3F86C7143284Q27009541-9E9BAC70-26A2-4FDC-8CD0-1D35A3B75C66Q27021705-AE775197-4275-4A37-A674-96E8276040EBQ27027547-653AC540-34E1-4935-9A2D-95A2FD2BB2ADQ27650471-D9B8BCFB-D0C0-4876-B071-7A47E6BA5868Q27654261-961C6463-8984-4004-84ED-6BE2EB091391Q27675453-6B66BC07-2FC6-4353-A848-569AE5AC5689Q28068988-5BC62EC6-04DA-4454-9912-3022FB1D8008Q28535348-4E54B8DC-F58D-423C-B3E4-4543D93C0012Q28729744-E6778C30-667A-4DB4-BCA0-1D7AEE18616EQ28829233-276DABC2-6663-45A5-B854-2D4C1C8146E9Q33410795-3D028578-9FD5-4033-A814-A699451163C7Q33455830-0FD9FB0F-01C7-4F25-B47E-4EB410E1DEE2Q33795023-6BF8FBE2-7C96-4F95-AD77-14BD27DC50B4Q33903025-DEC252A4-5AB7-4064-A1FC-2E3E2AF12434Q33905819-E65CDCA2-3D44-41FA-8FEC-4AB639851FEEQ33920919-85F43CEA-9F91-4EB7-84B3-87FB1682883CQ34145863-16BD7AB8-6B24-4902-8B84-720315F49F54Q34186928-AA69F62C-6869-41CD-8DAF-8EBF10F139DEQ34249937-231C0E2B-7F80-4AA1-AA0E-7F9458DD2C49Q34395222-6FFCF2BB-5013-44F2-86E3-CBA7048BD82FQ34395849-F57FA48A-6376-4972-90FC-28ABE650EF6CQ34493921-970FC481-9169-4FF9-A1ED-F804BDF94F44Q34496948-48944434-2590-400E-9463-6DDFABCA8310Q34560345-ECB8661E-122C-4088-9796-5F257734C17DQ34585223-EA2AAC62-13FF-4D8F-A6FF-461FF40B85DFQ34595188-E34F5C18-0502-430C-A98E-6F7B16DB5F6AQ34612619-C7E75183-E4E1-40B9-B8BA-8769C8E48B40Q34652408-2D820DC0-DFD2-4D53-A4C4-F9009FB1F9A2Q34677859-54C2C0C3-D018-40AB-8515-13A9A6D89237Q34681370-5FF3927F-EA61-4627-8E0A-3966B2116267Q34743969-73E35C6F-26CC-40B4-ADDA-B725D29D0041Q34749889-C64F58EE-D235-4678-9371-8BBB68BD8E1DQ34802235-D2F1D9BC-8C9D-4CFD-8883-7451743AE50FQ34939979-B7AC9528-4F47-4338-8BF5-2EDFA5B1F861Q35077632-8D05B7AA-9AF8-4A19-8469-BA9E6675C991Q35090079-0FD4D82F-90B8-4503-9F7B-592A745A7D94
P2860
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@ast
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@en
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@nl
type
label
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@ast
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@en
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@nl
prefLabel
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@ast
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@en
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@nl
P2093
P2860
P50
P3181
P1433
P1476
Targeting human {gamma}delta} ...... one-refractory prostate cancer
@en
P2093
Alfredo Salerno
Andrew Roberts
Fabio Fulfaro
Matilde D'Asaro
Nicola Gebbia
Serena Meraviglia
Simona Buccheri
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-07-0199
P407
P577
2007-08-01T00:00:00Z